Craniofacial abnormalities affect a significant proportion of society. Cleft lip and/or palate, for example, occurs in 1 per 500–700 births, depending on geography and ethnicity. The costs in terms of morbidity, psychological disturbance, and social and workplace exclusion are considerable for patients and their families, and society. The average incidence of new cleft cases is 2 clefts per 1,000 live births in the combined populations of Thailand, Bangladesh, Bhutan, Brunei, Cambodia, Indonesia, Laos, Malaysia, Nepal, Pakistan, Philippines, Singapore, Sri Lanka, and Vietnam.1
Cerebral palsy (CP) is one of the leading causes of childhood disability. It has been defined as ‘a disorder of movement and posture, causing activity limitation that is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain’.
Tocotrienols are one of the two classes of compounds generally known as vitamin E. Prominent researcher in pharmaceutical technology, Professor Yuen Kah Hay, recently spoke to MIMS Doctor about the neuroprotective benefits conferred by palm tocotrienols. He shared key insights from a clinical trial performed by his team and about the compound’s potential for clinical use.
There is no benefit to using ibuprofen over paracetamol in most patients with upper respiratory tract infections (URTIs). Steam inhalation therapy also does not offer any advantage, research has shown.